MARKET

KZIA

KZIA

Kazia
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.450
+0.030
+0.68%
Closed 16:00 12/12 EST
OPEN
4.350
PREV CLOSE
4.420
HIGH
4.450
LOW
4.274
VOLUME
43.81K
TURNOVER
--
52 WEEK HIGH
9.74
52 WEEK LOW
2.110
MARKET CAP
27.66M
P/E (TTM)
-3.5763
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of KZIA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

EPS

KZIA News

  • SBGL, OLLI among premarket gainers
  • Seeking Alpha - Article.1d ago
  • Kazia Initiates Preparatory Activities to Bring GDC-0084 into GBM AGILE, an International Phase II / III Study in Glioblastoma
  • PR Newswire.2d ago
  • Edison issues ADR outlook on Kazia Therapeutics (KZIA)
  • ACCESSWIRE.12/02 13:45
  • If You Had Bought Kazia Therapeutics (ASX:KZA) Shares A Year Ago You'd Have Made 60%
  • Simply Wall St..11/28 22:12

More

Industry

Biotechnology & Medical Research
+0.57%
Pharmaceuticals & Medical Research
+0.73%

Hot Stocks

Name
Price
%Change

About KZIA

Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate.
More

Webull offers Kazia Therapeutics Ltd (ADR) (KZIA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.